off-the-shelf– tag –
-
Fate Therapeutics to Present iPSC-Derived Cell Immunotherapy Pipeline Progress at Investor Conferences
Fate Therapeutics, Inc. USA Overview Fate Therapeutics announced its participation in several upcoming investor conferences during Q3 2026. The clinical-stage biopharmaceutical company focuses on developing innovative 'off-the-shelf' iPS... -
CAR-NK Cell Therapy for Solid Tumors: Promising Safety and Off-the-Shelf Potential Outpace CAR-T
Cell Reports Medicine (via PubMed) USA Overview A new review highlights chimeric antigen receptor (CAR)-modified natural killer (NK) cells as a promising immunotherapy strategy for solid tumor treatment. Compared to CAR-T cell therapy, C... -
USC Scientists Engineer ‘Endless Supply’ of iPSC-Derived Immune Cell Precursors to Supercharge Cancer Immunotherapy
ScienceDaily (University of Southern California) USA Overview University of Southern California (USC) scientists have successfully cultured a virtually limitless supply of immune cell precursors, inspired by induced pluripotent stem cell... -
UniXell Biotechnology Secures US FDA IND Clearance for Off-the-Shelf Parkinson’s Cell Therapy UX-DA003, Accelerating Dual China-US Clinical Development
BioPharma APAC USA Overview UniXell Biotechnology announced that its allogeneic iPSC-derived therapy UX-DA003 for Parkinson's disease has received Investigational New Drug (IND) approval from the US FDA. This approval enables the company... -
CAR-T Expands to Solid Tumors & Autoimmune Diseases; BAF CAR-T Shows Promising Early Results for Lupus, Compared with Off-the-Shelf CAR-NK Cells
University Hospitals USA Overview CAR-T cell therapy is expanding its success from hematologic malignancies to solid tumors and autoimmune diseases. Notably, early clinical trial results for BAF CAR-T in lupus are highly promising, sugge... -
Fate Therapeutics’ iPSC-Derived CAR-T FT836 Shows Early Phase 1 Data Suggesting Colorectal Tumor Shrinkage with Nine Engineered Edits
CRISPR Medicine News USA Overview Fate Therapeutics has announced initial Phase 1 data for FT836, an iPSC-derived, off-the-shelf CAR-T cell therapy. In a trial involving nine colorectal cancer patients, reductions in target lesion size a... -
CRISPR Medicine News Roundup: Sickle Cell CRISPR Drug Shows Potent Results in Young Children, Caribou’s Off-the-Shelf CAR-T Delivers Positive Phase 1 Data
CRISPR Medicine News USA Overview A CRISPR Medicine News summary article reports that the first approved CRISPR gene therapy for sickle cell disease demonstrated equally potent results in children as young as 5 years old. Additionally, C... -
Genomic Engineering Strategies and Alternative Cell Types in Allogeneic T-Cell Immunotherapy Platforms Enable Scalable Cancer Treatment
Academic Publication Global Overview Allogeneic T-cell therapy is emerging as a highly promising strategy in cancer immunotherapy due to its scalability and 'off-the-shelf' availability, overcoming logistical and manufacturing constraint... -
CRISPR Gene Editing Advances in 2026: Accumulation of Clinical Data and Evolving Regulatory Framework for Rare Diseases, Cancer, and Autoimmune Disorders
Industry report / Analysis USA Overview The CRISPR gene editing landscape in 2026 shows significant progress across rare diseases, hematologic and solid cancers, and autoimmune disorders. Clinical programs are generating crucial data, wh... -
CRISPR Therapeutics Stock Volatility Driven by CASGEVY Commercialization and CTX112 Clinical Progress
Investing.com USA Overview CRISPR Therapeutics has experienced significant stock volatility due to market reactions to the commercialization of its approved CRISPR gene therapy, CASGEVY, and clinical developments for its off-the-shelf CA...
